PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Bayer’s Nubeqa wins NICE prostate cancer backing

Bayer’s Nubeqa has scored backing from the UK’s National Institute for Health and Care Excellence (NICE) for treating non-metastatic castration-resistant prostate cancer (nmCRPC).

Nubeqa (darolutamide) has been authorised for use alongside androgen deprivation therapy (ADT). According to Bayer, it is the first treatment NICE has recommended in this indication.

The NICE recommendation is based on results from the phase III ARAMIS trial, which evaluated the efficacy and safety of Nubeqa plus ADT in nmCRPC patients.

In this trial, Nubeqa plus ADT demonstrated a statistically significant improvement in the primary efficacy endpoint of metastasis-free survival (MFS), with a median 40.4 months compared to 18.4 months for placebo plus ADT.

The final overall survival (OS) data – a secondary endpoint in the ARAMIS trial – demonstrated a significant improvement in OS compared to placebo plus ADT, with a 31% reduction in the risk of death.

“Bayer welcomes NICE’s positive recommendation for Nubeqa, ensuring men with nmCRPC who are at high risk of developing metastatic disease have access to therapeutic options that delay disease progression, whilst improving overall survival, when compared to placebo and ADT alone,” said Melissa Rowe, director of medical affairs for specialty medicine at Bayer UK.

“Bayer is dedicated to research that aims to address the unmet need in the way cancer is treated, with a particular focus on prostate cancer,” she added.

Prostate cancer is the most common cancer in men in the UK, with over 48,000 new cases each year on average.

Approximately a third of men with nmCRPC develop metastases within two years, highlighting the need for treatment which delay the development of metastases in this patient population.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026